Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 6

Newer treatments for fibromyalgia syndrome

Authors Richard E Harris, Daniel J Clauw

Published 5 December 2008 Volume 2008:4(6) Pages 1331—1342

DOI https://dx.doi.org/10.2147/TCRM.S3396

Review by Single-blind

Peer reviewer comments 5

Richard E Harris, Daniel J Clauw

Department of Anesthesiology, The University of Michigan, Ann Arbor, MI, USA

Abstract: Fibromyalgia syndrome is a common chronic pain disorder of unknown etiology. The lack of understanding of the pathophysiology of fibromyalgia has made this condition frustrating for patients and clinicians alike. The most common symptoms of this disorder are chronic widespread pain, fatigue, sleep disturbances, difficulty with memory, and morning stiffness. Emerging evidence points towards augmented pain processing within the central nervous system (CNS) as having a primary role in the pathophysiology of this disorder. Currently the two drugs that are approved by the United States Food and Drug Administration (FDA) for the management of fibromyalgia are pregabalin and duloxetine. Newer data suggests that milnacipran, a dual norepinephrine and serotonin reuptake inhibitor, may be promising for the treatment of fibromyalgia. A double-blind, placebo-controlled trial of milnacipran in 125 fibromyalgia patients showed significant improvements relative to placebo. Milnacipran given either once or twice daily at doses up to 200 mg/day was generally well tolerated and yielded significant improvements relative to placebo on measures of pain, patient’s global impression of change in their disease state, physical function, and fatigue. Future studies are needed to validate the efficacy of milnacipran in fibromyalgia.

Keywords: fibromyalgia, pain, pharmacological, treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials

Maneeton B, Maneeton N, Likhitsathian S, Suttajit S, Narkpongphun A, Srisurapanont M, Woottiluk P

Drug Design, Development and Therapy 2015, 9:1927-1936

Published Date: 1 April 2015

Unusually delayed presentation of persistent Descemet’s membrane tear and detachment after cataract surgery

Morkin MI, Hussain RM, Young RC, Ravin T, Dubovy SR, Alfonso EC

Clinical Ophthalmology 2014, 8:1629-1632

Published Date: 28 August 2014

Analysis of macular cone photoreceptors in a case of occult macular dystrophy

Tojo N, Nakamura T, Ozaki H, Oka M, Oiwake T, Hayashi A

Clinical Ophthalmology 2013, 7:859-864

Published Date: 8 May 2013

Intraocular pressure in Japanese diabetic patients

Matsuoka M, Ogata N, Matsuyama K, Yoshikawa T, Takahashi K

Clinical Ophthalmology 2012, 6:1005-1009

Published Date: 2 July 2012

Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LHBETATAG retinal tumors

Piña Y, Houston SK, Murray TG, Koru-Sengul T, Decatur C, Scott WK, Nathanson L, Clarke J, Lampidis TJ

Clinical Ophthalmology 2012, 6:817-830

Published Date: 29 May 2012

Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells

Kanmogne GD, Singh S, Roy U, Liu X, McMillan J, Gorantla S, Balkundi S, Smith N, Alnouti Y, Gautam N, Zhou Y, Poluektova L, Kabanov A, Bronich T, Gendelman HE

International Journal of Nanomedicine 2012, 7:2373-2388

Published Date: 8 May 2012

Is obesity in women protective against osteoporosis?

Migliaccio S, Greco EA, Fornari R, Donini LM, Lenzi A

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011, 4:273-282

Published Date: 4 July 2011

Bipolar disorder and neurophysiologic mechanisms

Simon M McCrea

Neuropsychiatric Disease and Treatment 2008, 4:1129-1153

Published Date: 5 December 2008

A single nucleotide polymorphism analysis of the LAMA1 gene in Japanese patients with high myopia

Sayaka Sasaki, Masao Ota, Akira Meguro, Ritsuko Nishizaki, Eiichi Okada, et al

Clinical Ophthalmology 2007, 1:289-295

Published Date: 15 December 2007